Details

Autor(en) / Beteiligte

• Lau, George
• Yu, Ming-Lung
• Wong, Grace
• Thompson, Alexander
• Ghazinian, Hasmik
• Hou, Jin-Lin
• Piratvisuth, Teerha
• Jia, Ji-Dong
• Mizokami, Masashi
• Cheng, Gregory
• Chen, Guo-Feng
• Liu, Zhen-Wen
• Baatarkhuu, Oidov
• Cheng, Ann Lii
• Ng, Woon Leung
• Lau, Patrick
• Mok, Tony
• Chang, Jer-Ming
• Hamid, Saeed
• Dokmeci, A. Kadir
• Gani, Rino A.
• Payawal, Diana A.
• Chow, Pierce
• Park, Joong-Won
• Strasser, Simone I.
• Mohamed, Rosmawaiti
• Win, Khin Maung
• Tawesak, Tanwandee
• Sarin, Shiv Kumar
• Omata, Masao

Titel

APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy

Ist Teil von

• Hepatology international, 2021-10, Vol.15 (5), p.1031-1048

Ort / Verlag

New Delhi: Springer India

Erscheinungsjahr

2021

Quelle

MEDLINE

Beschreibungen/Notizen

• Background & Aim Hepatitis B reactivation related to the use of immunosuppressive therapy remains a major cause of liver-related morbidity and mortality in hepatitis B endemic Asia-Pacific region. This clinical practice guidelines aim to assist clinicians in all disciplines involved in the use of immunosuppressive therapy to effectively prevent and manage hepatitis B reactivation. Methods All publications related to hepatitis B reactivation with the use of immunosuppressive therapy since 1975 were reviewed. Advice from key opinion leaders in member countries/administrative regions of Asian-Pacific Association for the study of the liver was collected and synchronized. Immunosuppressive therapy was risk-stratified according to its reported rate of hepatitis B reactivation. Recommendations We recommend the necessity to screen all patients for hepatitis B prior to the initiation of immunosuppressive therapy and to administer pre-emptive nucleos(t)ide analogues to those patients with a substantial risk of hepatitis and acute-on-chronic liver failure due to hepatitis B reactivation.